If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
NEPHROLOGY
ISSN 2053-4248 July 2014 • emjreviews.com
INSIDE
Review of
ERA-EDTA 2014
Amsterdam, the Netherlands
CONTENTS
EDITORIAL BOARD................................................................................................................................. 4
CONGRESS REVIEW............................................................................................................................... 8
• Review of the 51st European Renal Association - European Dialysis and Transplant
Association Congress, held in Amsterdam, the Netherlands, 31st May-3rd June 2014
SYMPOSIUM REVIEWS
• Diagnostic Challenges in Thrombotic Microangiopathies...................................................... 28
• Bringing the Benefits of High-Dose Haemodialysis to the Home with a Novel
Haemodia
NEPHROLOGY ISSN 2053-4248
CONTENTS EDITORIAL BOARD.......................
NEPHROLOGY NO ADDED MORTALITY BENEFIT FROM CUR
Editorial Board Nephrology Editor-in-Chief: Pro
Welcome I would like to welcome you all to this s
SUBSCRIBE TO THE EMJ NEWSLETTER www.news.emjre
Foreword Prof Norbert Lameire Emeritus Professor
ERA-EDTA ANNUAL CONGRESS 2014 AMSTERDAM RAI EXHIB
Welcome to the European Medical Journal review of
ERA-EDTA ANNUAL CONGRESS 2014 AMSTERDAM RAI EXHIB
clinical, scientific, and political channels. All
ERA-EDTA ANNUAL CONGRESS 2014 AMSTERDAM RAI EXHIB
Diabetes causing trouble in kidney disease Ass
ERA-EDTA ANNUAL CONGRESS 2014 AMSTERDAM RAI EXHIB
The quest to eliminate tuberculosis faces a long
ERA-EDTA ANNUAL CONGRESS 2014 AMSTERDAM RAI EXHIB
ERA-EDTA Congress 2014- Europe’s premier conferen
ERA-EDTA ANNUAL CONGRESS 2014 AMSTERDAM RAI EXHIB
CCL2 inhibition may hinder CKD progression INHIB
ERA-EDTA ANNUAL CONGRESS 2014 AMSTERDAM RAI EXHIB
Ray of hope for risky nephropathy therapy Nephro
ERA-EDTA ANNUAL CONGRESS 2014 AMSTERDAM RAI EXHIB
Iron-clad solution to anaemia control A TWO-IN
ERA-EDTA ANNUAL CONGRESS 2014 AMSTERDAM RAI EXHIB
Canagliflozin treatment for Type 2 diabetics can l
ERA-EDTA ANNUAL CONGRESS 2014 AMSTERDAM RAI EXHIB
SUBSCRIBE FREE TO OUR YOUTUBE CHANNEL www.youtube
DIAGNOSTIC CHALLENGES IN THROMBOTIC MICROANGIOPAT
Condition directly causes TMA • Uncontrolled com
In summary, TMA is a serious rapidly progressing
Thrombocytopenia
1 year later the patient was in good condition wi
29.3 mL/min/1.73m2: Mean change from baseline in
Table 1: Results of eculizumab use in patients wi
outcomes.32,50,51 Eculizumab is well tole
39. Licht C et al. 2013; Abstract Pre
BRINGING THE BENEFITS OF HIGH-DOSE HAEMODIA
HD-Induced Myocardial Stunning Leads to Myocardia
FA in the Group Dialysed at 370C P=0.001 Z69
The effect of dialysis on weight gain
Table 1: Acute haemodynamic (HD) effects in exten
also been established that high-dose and home HD
Extended Use of the Dialyser by Category of
BMC Nephrol. 2012;13:45. 10. Jefferies HJ e
PAIN IN AUTOSOMAL DOMINANT POLYCYSTIC
white blood cell (WBC) count >10,000/µl, or
to the pain management in ADPKD, in which, at the
As a consequence, the most common extrarenal mani
Additionally, asymmetry in renal cyst enlargement
29. Ubara Y et al. Renal contraction therap
AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE:
clinic? Which imaging in which patients? Whom sho
(such as control of urinary tract inf
addition of alpha keto-analogues.55,56 Within
5,46 3,26 13,15 7,64 6,53 5,48 5,39 7,55 6,45
Sc. 2.1/17 TSE / SE/M [24] 08-gen-2014 09:56:24
R L -460,01 Fused Transaxials P R L
A partial exception to the inconsistency of the t
Chronic Kidney Dis. 2010;17(2):131-9. 11. Watnick
new treatments in autosomal dominant polycystic k
AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE:
vascular sclerosis, and interstitial fibrosis.
should be regularly monitored by the nephrologist
and higher haemoglobin levels.51 In another study
with MRA should be performed in high-risk A
polycystic kidney disease. Am J Kidney Dis. 2000;
CHRONIC KIDNEY DISEASE – WHERE NEXT? PREDICTIN
glomerular filtration rate (eGFR) the risk of reac
However, since the numbers at risk are so small i
(b) 75+ 65-74 Age (years) 55-64 18-54 (d) (1
models, including a comparison with the
Table 1 continued. Study Setting, included indivi
Table 2: Common and expected indices for the repo
far, provided limited improvement in mo
kidney disease in the united states. JAMA. 2007;2
NO ADDED MORTALITY BENEFIT FROM CURRENT APPROACHE
remains the best evidence to date that haemodialy
or 24-hour CVVH.22 However, more data are needed
In the absence of robust predictive markers of re
clinical practice. The weight-adjusted effluent fl
REFERENCES 1. Bellomo R et al. Acute kidney inju
2010;5(6):956-63. 41. Lehner G et al. H
THE MULTIDISCIPLINARY APPROACH TO RENAL
Smoking Leptin Drugs
Therefore, it is fundamental to assess the econom
and/or poor compliance. In this setting the
represent a novel solution. Catheter-based RD is
Table 2: RD clinical trials in resistant hyperten
consequences in hypertension) with respect to SoC
10. Schlaich MP et al. Renal denervation as a the
CHRONIC RENAL ALLOGRAFT DYSFUNCTION ANT
Epidemiology Due to the continuous evolution of t
More recently, a study by Lynch and colleagues29
100 90 Normal80 Graft survival Fibr 70Fib
on renal biopsies. Search of circulating DS
treatment in patients affected by cABMR. Billing
100 90 80 % 70DSA negative DSA positiv
REFERENCES 1. L’Agence de la biomédecine. Agence
of follow-up biopsies. Am J Transplant. 2013;13(9
PREGNANCY IN SYSTEMIC LUPUS ERYTHEMATOSUS
renal insufficiency10 and with the lowest pregnan
associated with the rate of active LN, did correl
Table 2: Clinical and laboratory features aiding
SUMMARY Although at increased risk of
THE USE OF VAPTANS IN HYPONATRAEMIA
Hyponatraemia also represents an economic and soc
be considered, especially when risk factors for t
Table 2: Main properties of the vasopressin recep
Indications for the use of tolvaptan in
results in terms of efficacy and safety.36 Anothe
the maximum dose approved for hyponatraemia treat
regarding the management of hyponatra
CARDIOVASCULAR REMODELLING IN CHRONIC K
haemodynamic factors that promote bot
of HF.13 Many commonly used biomarkers are
mitigating the effects of calcitriol on int
CV protection with antiplatelet and anticoagulant
REFERENCES 1. Foley RN et al. Clinical
Chronic Kidney Dis. 2011;18(4):249–57. 58
WHAT’S NEW Icy frontiers explored in kidney trans
NEPHROLOGY 25 years of improvement for child kidn
WHAT’S NEW Oxygen starved cells promote kidney ca
NEPHROLOGY Battle of the bulge BELLY fat of rats
WHAT’S NEW Increased risk of kidney disease to ki
NEPHROLOGY No stone left unturned in single opera
WHAT’S NEW Acute kidney injury sufferers on dialy
From a host of fifteen therapeutic areas, EUROPEAN
Featured Suppliers Nephrology With its headquar
Mission ERA-EDTA´s Promoting Kidney Health and I
Buyer’s Guide Exhibitors • ABBVIE INC. • ACTUA
• HERCO WASSERTECHNIK • IMMUNDIAGNOSTIK • INFOM
UPCOMING EVENTS World Transplant Congress (WTC)
NEPHROLOGY Primary Care: Nephrology Essentials a
SUBSCRIBE TO RECEIVE THE LATEST CATIONS PUBLI